| Polynucleotides and polypeptides of the erythropoietin gene -> Monitor Keywords |
|
|
 
Polynucleotides and polypeptides of the erythropoietin geneRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Cyclopeptides, 25 Or More Peptide Repeating Units In Known Peptide Chain StructurePolynucleotides and polypeptides of the erythropoietin gene description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060211618, Polynucleotides and polypeptides of the erythropoietin gene. Brief Patent Description - Full Patent Description - Patent Application Claims
RELATED APPLICATIONS [0001] The present application is a divisional application of U.S. patent application Ser. No. 10/113,824 filed on Mar. 29, 2002 which claims benefit of U.S. Provisional Applications 60/358,598 filed on Feb. 21, 2002, 60/345,440 filed on Jan. 4, 2002 and 60/343,163 filed on Dec. 21, 2001. This application also claims foreign priority from French application No. FR0104603 filed on Apr. 4, 2001. BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to new polynucleotides deriving from the nucleotide sequence of the erythropoietin gene (EPO) and comprising new SNPs, new polypeptides derived from the natural erythropoietin protein and comprising mutations caused by these SNPs as well as their therapeutic uses. [0004] 2. Related Art [0005] The erythropoietin gene, hereinafter referred to as EPO, is described in the publication Jacobs K. et al. (1985) "Isolation and characterization of genomic and cDNA clones of human erythropoietin"; Nature 313 (6005), 806-810. [0006] The nucleotide sequence of this gene is accessible under accession number X02158 in the GenBank database. [0007] The erythropoietin is known to act on proliferation, differentiation, and maturation of progenitor cells of erythropoiesis. It determines their differentiation and maturation into erythrocytes. [0008] EPO is also known to act as autocrine factor on cerain erythroleukemic cells and to be a mitogen and a chemoattractant for endothelial cells. [0009] EPO is also known to stimulate activated and differentiated B-cells and to enhance B-cell immunoglobulin production and proliferation. [0010] EPO synthesis is subject to a complex control circuit which links kidney and bone marrow in a feedback loop. Synthesis depends on venous oxygen partial pressure and is increased under hypoxic conditions. [0011] EPO production is influenced also by a variety of other humoral factors, such as testosterone, thyroid hormone, growth hormone, and catecholamines. In contrast, several cytokines such as IL-1, IL-6, and TNF-alpha, reduce EPO synthesis. [0012] In the cell, binding of EPO to its receptor induces: [0013] a release of membrane phospholipids, [0014] the synthesis of diacyl glycerol, [0015] an increase in intracellular calcium levels, [0016] an increase in intracellular pH, and [0017] an increase in intracellular phospholipase A2 and phospholipase C, the latter inducing fos and myc oncogenes. [0018] Excess of EPO is known to lead to erythrocytosis. This is accompanied by an increase in blood viscosity and cardiac output and may lead also to heart failure and pulmonary hypertension. A significant reduction of platelets is also observed. [0019] Thrombosis is another adverse effect of an excess of EPO. [0020] Pulmonary and cerebral embolism, i.e. the sudden obliteration of a blood vessel by a clot or an extraneous compound transported by the blood, also constitutes a serious adverse effect related to EPO consumption. [0021] However, when the amount of synthesized EPO is too low as it is in the case of severe kidney insufficiencies, anemias are often observed. Thus, EPO is often administered to patients with severe kidney insufficiency, with hematocrit below 0.3, in particular in dialysis patients. [0022] The most important complication in the treatment with EPO is hypertony, the increases in urea, potassium, and phosphate levels, an increase in blood viscosity, an expansion of thrombopoietic progenitor cells and circulating platelets. [0023] EPO is also used to activate erythropoiesis, allowing the collection of autologous donor blood. [0024] Moreover, EPO use has been suggested also for non-renal forms of anemia induced, for example, by chronic infections, inflammatory processes, radiation therapy, and cytostatic drug treatment. [0025] To a certain extent EPO is also a stimulating factor of megakaryocytopoiesis. The activity of EPO is synergized by IL-4. [0026] EPO seems to possess neuroprotective capabilities since it has been demonstrated that EPO protects neurons against cell death induced by ischemia, probably by reducing free radicals production and by reducing oxidative stress effects. [0027] It is known that the EPO gene is involved in different human disorders and/or diseases, such as different cancers like carcinomas, melanomas, myelomas, tumors, leukemia, and cancers of the liver, neck, head, and kidneys; cardiovascular diseases such as brain injury; metabolic diseases such as those not related to the immune system like obesity; infectious diseases, in particular viral infections such as Hepatitis B, Hepatitis C, and AIDS; pneumonia; ulcerative colitis; central nervous system diseases such as Alzheimer's disease, schizophrenia, and depression; tissue or organ graft rejection; wounds healing; anemia; allergy; asthma; multiple sclerosis; osteoporosis; psoriasis; rheumatoid arthritis; Crohn's disease; autoimmune diseases and disorders; genital or venereal warts; gastrointestinal disorders; and disorders related to treatments by chemotherapy. Continue reading about Polynucleotides and polypeptides of the erythropoietin gene... Full patent description for Polynucleotides and polypeptides of the erythropoietin gene Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Polynucleotides and polypeptides of the erythropoietin gene patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Polynucleotides and polypeptides of the erythropoietin gene or other areas of interest. ### Previous Patent Application: Peptide yy analogs Next Patent Application: Polypeptides having antimicrobial activity and polynucleotides encoding same Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Polynucleotides and polypeptides of the erythropoietin gene patent info. IP-related news and info Results in 0.14023 seconds Other interesting Feshpatents.com categories: Canon USA , Celera Genomics , Cephalon, Inc. , Cingular Wireless , Clorox , Colgate-Palmolive , Corning , Cymer , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
